Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF
Objectives: The authors sought to examine the effect of dapagliflozin across the spectrum of risk in patients enrolled in DAPA-HF. Background: In the DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin decrease...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier Inc.
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |